-
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.
J Virol. 1994 Sep;68(9):6006-13
PMID: 8057475
-
Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development.
AIDS Res Hum Retroviruses. 1994 Jun;10(6):631-2
PMID: 8074926
-
Neutralization of HIV-1.
AIDS Res Hum Retroviruses. 1994 Jun;10(6):633-43
PMID: 8074927
-
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.
J Virol. 1994 Nov;68(11):6994-7000
PMID: 7933081
-
Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
Virology. 1994 Nov 1;204(2):609-15
PMID: 7941328
-
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.
J Virol. 1994 Dec;68(12):8312-20
PMID: 7525987
-
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
Science. 1994 Nov 11;266(5187):1024-7
PMID: 7973652
-
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.
J Virol. 1995 Jan;69(1):101-9
PMID: 7527081
-
A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.
J Virol. 1995 Jan;69(1):122-30
PMID: 7527082
-
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
J Infect Dis. 1997 Oct;176(4):924-32
PMID: 9333150
-
Inhibition of HIV-1 infection by the beta-chemokine MDC.
Science. 1997 Oct 24;278(5338):695-8
PMID: 9381181
-
HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals.
Nat Med. 1997 Nov;3(11):1250-7
PMID: 9359700
-
The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.
J Virol. 1997 Dec;71(12):9198-205
PMID: 9371578
-
Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.
J Gen Virol. 1998 Jan;79 ( Pt 1):77-82
PMID: 9460926
-
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
J Virol. 1998 Mar;72(3):1876-85
PMID: 9499039
-
Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.
J Virol. 1998 Mar;72(3):1886-93
PMID: 9499040
-
Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.
J Virol. 1998 Mar;72(3):2491-5
PMID: 9499111
-
Interplay of HIV-1 phenotype and neutralizing antibody response in pathogenesis of AIDS.
Immunol Lett. 1996 Jun;51(1-2):23-8
PMID: 8811340
-
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202
PMID: 2452447
-
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.
J Virol Methods. 1988 Aug;20(4):309-21
PMID: 2460479
-
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72
PMID: 2771954
-
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
Science. 1990 Dec 14;250(4987):1590-3
PMID: 1703322
-
Immunodominance and antigenic variation of the principal neutralization domain of HIV-1.
Virology. 1991 Apr;181(2):481-9
PMID: 2014634
-
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.
Science. 1991 Jul 5;253(5015):71-4
PMID: 1905842
-
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.
N Engl J Med. 1995 Jan 26;332(4):201-8
PMID: 7808485
-
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
J Virol. 1995 Sep;69(9):5723-33
PMID: 7543586
-
High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors.
J Virol. 1995 Sep;69(9):5838-42
PMID: 7637030
-
Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
J Immunol. 1995 Oct 15;155(8):4100-10
PMID: 7561123
-
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
J Virol. 1995 Nov;69(11):6609-17
PMID: 7474069
-
Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies.
AIDS. 1995 Aug;9(8):867-74
PMID: 7576320
-
HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women.
Nat Med. 1995 Jan;1(1):59-64
PMID: 7584954
-
Neutralizing antibodies in slowly progressing HIV-1 infection.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Dec 1;10(4):400-7
PMID: 7583435
-
HIV suppression by interleukin-16.
Nature. 1995 Dec 7;378(6557):563
PMID: 8524386
-
Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.
J Virol. 1996 Jan;70(1):427-44
PMID: 8523556
-
Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.
J Virol. 1996 Jan;70(1):445-58
PMID: 8523557
-
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.
Science. 1995 Dec 15;270(5243):1811-5
PMID: 8525373
-
Toward an understanding of the correlates of protective immunity to HIV infection.
Science. 1996 Jan 19;271(5247):324-8
PMID: 8553066
-
Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection.
AIDS Res Hum Retroviruses. 1995 Oct;11(10):1153-62
PMID: 8573370
-
Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
AIDS Res Hum Retroviruses. 1995 Nov;11(11):1379-91
PMID: 8573396
-
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
J Infect Dis. 1996 Feb;173(2):340-8
PMID: 8568294
-
Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Apr 15;11(5):438-47
PMID: 8605588
-
Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.
J Virol. 1996 Jun;70(6):3668-77
PMID: 8648701
-
Likely HIV cofactor found.
Science. 1996 May 10;272(5263):809-10
PMID: 8629006
-
Chemokine receptors and HIV-1: an attractive pair?
Cell. 1996 Jul 12;86(1):1-3
PMID: 8689676
-
Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.
AIDS Res Hum Retroviruses. 1996 May 1;12(7):585-92
PMID: 8743084
-
Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.
J Virol. 1996 Sep;70(9):6136-42
PMID: 8709238
-
HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.
AIDS. 1995;9 Suppl A:S117-36
PMID: 8819579
-
Early phases of HIV type 1 infection.
AIDS Res Hum Retroviruses. 1996 Jan 1;12(1):1-9
PMID: 8825612
-
Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression.
J Gen Virol. 1996 Oct;77 ( Pt 10):2403-14
PMID: 8887471
-
Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.
J Virol. 1996 Nov;70(11):7827-32
PMID: 8892904
-
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.
Nature. 1996 Nov 14;384(6605):184-7
PMID: 8906796
-
Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro.
AIDS Res Hum Retroviruses. 1997 Jan 1;13(1):19-27 "[|
PMID: 8989423
-
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
J Virol. 1997 May;71(5):3734-41
PMID: 9094648
-
Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses.
J Virol. 1997 Jun;71(6):4284-95
PMID: 9151816
-
Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.
J Immunol. 1997 Jul 1;159(1):279-89
PMID: 9200464
-
Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry.
Virology. 1997 Sep 1;235(2):179-90
PMID: 9281497
-
Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.
Science. 1991 Oct 4;254(5028):105-8
PMID: 1718036
-
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.
Nature. 1992 Feb 20;355(6362):728-30
PMID: 1741059
-
V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity.
Virology. 1992 Apr;187(2):423-32
PMID: 1546447
-
CD8+ cell anti-HIV activity: nonlytic suppression of virus replication.
AIDS Res Hum Retroviruses. 1992 Jun;8(6):1039-50
PMID: 1354466
-
Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1.
Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9434-8
PMID: 1409653
-
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
J Virol. 1993 Feb;67(2):863-75
PMID: 7678308
-
Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
J Infect Dis. 1993 Jul;168(1):207-10
PMID: 8515110
-
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
J Virol. 1993 Nov;67(11):6642-7
PMID: 7692082
-
Diversity of the V3 region of HIV in Paris, France.
AIDS. 1993 Sep;7(9):1199-204
PMID: 8216976
-
Jitters jeopardize AIDS vaccine trials.
Science. 1993 Nov 12;262(5136):980-1
PMID: 8235635
-
Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.
J Virol. 1994 Jan;68(1):469-84
PMID: 7504741
-
V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1.
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11518-22
PMID: 7505441
-
Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.
J Virol. 1994 Jun;68(6):3908-16
PMID: 8189527
-
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
J Virol. 1994 Jul;68(7):4650-5
PMID: 8207839
-
Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp120 V3 domain.
AIDS Res Hum Retroviruses. 1994 Mar;10(3):245-51
PMID: 8018385
-
Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.
J Virol. 1994 Aug;68(8):5142-55
PMID: 8035514
-
Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.
J Virol. 1994 Aug;68(8):5264-9
PMID: 8035523